Screener
Regeneron Pharmaceuticals REGN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's return on equity?
- Regeneron Pharmaceuticals (REGN) reported return on equity of 14% in Q2 2026.
- How has Regeneron Pharmaceuticals's return on equity changed year-over-year?
- Regeneron Pharmaceuticals's return on equity decreased by 8.4% year-over-year, from 15.3% to 14%.
- What is the long-term trend for Regeneron Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's return on equity has grown at a -14.1% compound annual growth rate (CAGR), from 31.8% to 14.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Regeneron Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude